Factors to Note Before Buying Endo International plc (ENDP)

Ivan Schwartz
August 22, 2017

Other equities analysts have also issued reports about the company.

The company surged 1.04% and closed its last trading session at $8.63. Finally, Cowen and Company reiterated a "hold" rating and set a $16.00 target price on shares of Endo International PLC in a research note on Thursday, August 10th.

Additionally on 8/09/17 Deutsche Bank "Maintained" Endo Int'l Plc (NASDAQ:ENDP) to Buy setting price target at $13 and on 6/16/17 Cantor Fitzgerald "Initiates Coverage On" the stock to Neutral at $12. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating to the company's stock. The stock presently has a consensus rating of "Hold" and an average target price of $14.75.

5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of Endo International plc (ENDP) stands at 9.69 while the industry's and the sector's growth for next 5 years ticked at 10.41 and 10.61 respectively. The stock price also has got the drift of -31.30% off from the 200-day moving average. For the current year the company's revenue estimates are $3.47 Billion compared to low analyst estimates of $3.4 Billion and high estimates of $3.52 Billion according to 18 number of analysts. The Market Capitalization of the company stands at 1.93 Billion.

Led strikes kill 42 civilians in Syria's Raqqa
It is estimated that some 300,000 civilians are trapped inside Raqqah, including 80,000 displaced from other parts of Syria.

Google said to be working on mini Google Home smart speaker
Google is planning two new Pixel smartphones , a Pixel-branded Chromebook , and a smaller version of the Home, Android Police reported .

Pilot Killed In Oregon Plane Crash Identified As Menlo Park Resident
The small fire that resulted from the crash is no longer a threat to the area and no other property was damaged. The amateur-built plane is registered to Mark Rich, according to Federal Aviation Administration records.

Here is the rundown on market activity for Endo International plc - Ordina (NASDAQ:ENDP). The consensus mean EPS for the current quarter is at $0.66 derived from a total of 17 estimates from the analysts who have weighed in on projected earnings. The Return on Equity (ROE) value stands at -174.5%. The company had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. During the same quarter in the previous year, the business earned $0.86 EPS. Endo International PLC's revenue was down 4.9% compared to the same quarter past year.

Many analysts are providing their Estimated Earnings analysis for Endo International plc and for the current quarter 17 analysts have projected that the stock could give an Average Earnings estimate of $0.66/share. If you are reading this piece of content on another domain, it was stolen and reposted in violation of U.S. & global trademark & copyright laws. BMO Capital Markets reiterated a "market perform" rating and set a $11.00 target price (down previously from $15.00) on shares of Endo International PLC in a research note on Friday, August 11th. Following the completion of the transaction, the executive vice president now owns 6,984 shares of the company's stock, valued at $56,011.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Ameriprise Financial Inc. now owns 554,138 shares of the company's stock worth $6,185,000 after buying an additional 483,545 shares during the last quarter. The shares were purchased at an average price of $7.89 per share, for a total transaction of $51,285.00. Following the transaction, the chief operating officer now owns 181,369 shares of the company's stock, valued at $1,396,541.30. Insiders have acquired 36,000 shares of company stock worth $279,460 in the last 90 days. Earnings surprises can have a huge impact on a company's stock price. OppenheimerFunds Inc. now owns 2,873,153 shares of the company's stock worth $32,065,000 after buying an additional 1,857,678 shares during the last quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company's stock valued at $544,000 after buying an additional 677 shares in the last quarter. First Quadrant L P CA purchased a new stake in Endo International PLC during the first quarter worth $24,556,000. Finally, Ameriprise Financial Inc. boosted its stake in shares of Endo International PLC by 685.0% in the first quarter. Diamond Hill Capital Management Inc. bought a new position in Endo International PLC during the second quarter worth approximately $5,454,000. The company rocked its 52-Week High of $24.93 and touched its 52-Week Low of $7.41. Hedge funds and other institutional investors own 92.27% of the company's stock.

The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX.

Other reports by GizPress

Discuss This Article

FOLLOW OUR NEWSPAPER